Wyost (denosumab-bddz) approved by FDA for treatment of Osteoporosis, Bone complications from cancer, and Giant Cell Tumor of Bone.
What is Wyost® Wyost® (denosumab-bbdz) is an FDA-approved biosimilar to denosumab, used for treating bone-related conditions such as preventing bone complications in patients with multiple myeloma, treating adults and adolescents with giant cell tumor of bone, and treating hypercalcemia of malignancy that does not respond to standard therapies. Wyost FDA Approval Manufacturer: Sandoz Inc. On […]